Critical analysis of the use of β-site amyloid precursor protein-cleaving enzyme 1 inhibitors in the treatment of Alzheimer’s disease

Genevieve Evin1,2
Adel Barakat2
1Oxidation Biology Laboratory, Mental Health Research Institute, Florey Institute of Neuroscience and Mental Health, University of Melbourne, 2Department of Pathology, University of Melbourne, Parkville, VIC, Australia

Abstract: Alzheimer’s disease (AD) is the major cause of dementia in the elderly and an unmet clinical challenge. A variety of therapies that are currently under development are directed to the amyloid cascade. Indeed, the accumulation and toxicity of amyloid-β (Aβ) is believed to play a central role in the etiology of the disease, and thus rational interventions are aimed at reducing the levels of Aβ in the brain. Targeting β-site amyloid precursor protein-cleaving enzyme (BACE)-1 represents an attractive strategy, as this enzyme catalyzes the initial and rate-limiting step in Aβ production. Observation of increased levels of BACE1 and enzymatic activity in the brain, cerebrospinal fluid, and platelets of patients with AD and mild cognitive impairment supports the potential benefits of BACE1 inhibition. Numerous potent inhibitors have been generated, and many of these have been proved to lower Aβ levels in the brain of animal models. Over 10 years of intensive research on BACE1 inhibitors has now culminated in advancing half a dozen of these drugs into human trials, yet translating the in vitro and cellular efficacy of BACE1 inhibitors into preclinical and clinical trials represents a challenge. This review addresses the promises and also the potential problems associated with BACE1 inhibitors for AD therapy, as the complex biological function of BACE1 in the brain is becoming unraveled.

Keywords: amyloid, dementia, secretase, aspartyl protease, neuregulin

Introduction

Alzheimer’s disease (AD) is a neurodegenerative disease of the central nervous system, which accounts for most cases of dementia in the elderly.1 AD has become an increasing socioeconomic burden, as it remains an unmet clinical challenge, with currently no treatment being available to halt or reverse its devastating effects. Various underlying factors, such as stroke, high blood pressure and hypercholesterolemia, diabetes, oxidative stress and inflammation, as well as sedentary lifestyle, which have been associated with AD, all converge to molecular mechanisms centered on the amyloid cascade theory.2,3 For over a century, AD has been traditionally diagnosed postmortem by the accumulation of amyloid plaques and τ-neurofibrillary tangles in the brain cortical regions and hippocampus.2 The major component of the amyloid plaques was identified nearly 30 years ago as a 4 kDa peptide fragment, termed amyloid-β (Aβ) peptide,4,5 and since then extensive research has aimed to reveal the pathological mechanisms that lead to neurodegeneration and AD pathogenesis.2 The most common hypothesis states that an imbalance between the production and clearance of Aβ peptides causes the formation of toxic Aβ species, and thereby triggers the dysfunction and death of neuronal cells.6,7 This is strongly supported by genetic studies that have identified disease-causative mutations in the genes encoding the Aβ precursor protein (APP)
and the presenilins, which code for catalytic subunits of γ-secretase, the proteolytic enzyme that dictates the length of Aβ isoforms being generated, and thus their aggregating and toxic properties. An APP mutation, which impairs cleavage by β-secretase, and thereby Aβ production, was recently discovered in Finnish families. This mutation appears to protect its carriers against cognitive decline and AD, further supporting the amyloid theory. Other susceptibility genes are also implicated in the cellular pathways that control Aβ production and clearance, such as apolipoprotein E, clusterin, α-macroglobulin, or sortilin. Aβ peptides self-associate to form oligomers, which seed amyloid-plaque deposition, but also, more importantly, which operate as toxic species. Aβ toxicity induces a vicious circle of neuronal inflammation, oxidative stress, altered metal-ion homeostasis, and metal toxicity, which all in turn increase Aβ production. Aβ toxicity also alters kinase and phosphatase activities, leading to the hyperphosphorylation of microtubule-associated tau, resulting in microtubule destabilization and the formation of τ-neurofibrillary tangles. Therefore, present efforts from both academia and the pharmaceutical industry aim at implementing strategies to prevent Aβ accumulation in the brain. Currently, therapeutic approaches are targeted at either preventing Aβ production by inhibiting the secretase enzymes that are involved in its production, or at interfering with its aggregation by using metal modulators or competing molecules, or at facilitating its clearance through immunotherapy. The present review focuses on the first approach, more specifically on the inhibition of β-site APP-cleaving enzyme (BACE)-1.

**BACE1 and Aβ amyloid production**

Aβ is a proteolytic fragment derived from the APP. The APP membrane receptor is involved in the regulation of neuronal activity, synaptic function, neurogenesis, and metal homeostasis. APP undergoes proteolytic processing through two alternative cellular metabolic pathways, as illustrated in Figure 1. Aβ is produced through the so-called amyloidogenic pathway. This involves sequential cleavages by the β-secretase enzyme BACE1 and by γ-secretase. The initial cleavage by BACE1 secretes the APP extracellular domain (sAPPβ) and generates a membrane-tethered 99-amino acid carboxyl terminal fragment (C99). Subsequent γ-secretase processing of C99 releases Aβ in the intraluminal/extracellular side and the APP intracellular domain (AICD) in the cytosol. sAPPβ is further processed by an unknown protease to release a small N-terminal fragment that can activate death receptor 6 (DR6). In a competing cellular pathway, termed nonamyloidogenic, APP is processed by α-secretase that sheds the APP ectodomain sAPPα by cleaving at an alternate site within the Aβ sequence and sixteen residues downstream from the β-secretase cleavage site. Further processing of the corresponding C-terminal fragment (C83) by γ-secretase produces the 3 kDa p3 peptide and AICD. In the AD brain, the balance shifts towards the amyloidogenic pathway.

![Figure 1](https://www.dovepress.com/)

**Figure 1** Disruption of the processing balance of the amyloid precursor protein (APP) in Alzheimer’s disease. The APP can be processed through two alternative pathways. In the α-secretase (α-secret) pathway (or nonamyloidogenic pathway), APP is cleaved by α-secret, which releases the soluble sAPPα N-terminal fragment, creating a membrane-tethered, C-terminal fragment of 83 amino acids (C83). α-Secretase (α-secret) cleavage occurs within the amyloid-β (Aβ) domain (shown in dark red) and precludes Aβ formation. C83 is further processed by γ-secretase (γ-secret) to produce the 3 kDa, nonamyloidogenic peptide p3 and release the APP intracellular domain (AICD), shown in light green, in the cytosol. In the β-secretase pathway (or amyloidogenic pathway), cleavage by β-secret APP-cleaving enzyme (BACE1) releases the soluble APP N-terminal fragment (sAPPα), which can be further processed by an unknown protease to liberate a fragment (shown in lilac) that can activate DR6 receptors. BACE1 cleavage of APP also produces the membrane-tethered C-terminal fragment of 99 amino acids (C99), which is the direct precursor to Aβ. Further processing of C99 by γ-secretase achieves the release of Aβ in the extracellular or intravesicular space and AICD in the cytosol. When Aβ production reaches a threshold, the peptide self-aggregates to form toxic oligomers that trigger degeneration of neuronal cells by a mechanism that involves free radical formation and shifts the balance of APP processing towards the amyloidogenic pathway.
about half of AD cases, and is attributed to alterations of posttranscriptional and posttranslational mechanisms.\textsuperscript{36,38,42} BACE1 activity is also elevated in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment (MCI) and with AD,\textsuperscript{43–45} but its levels may vary as the disease progresses, being actually lower at the more advanced stages of the illness, due to the loss of neurons that are the brain’s cell population with higher BACE1 expression.\textsuperscript{46} Increased CSF BACE1 activity in MCI patients correlates with changes in hippocampal volume and with the APOE e4 genotype.\textsuperscript{47} BACE1 activity is also elevated in platelets of patients with AD and MCI.\textsuperscript{48,49} The other enzymatic activity that is directly implicated in Aβ formation is γ-secretase, a multimeric membrane-embedded proteolytic complex, where presenilin (either presenilin 1 or presenilin 2) acts as the catalytic subunit.\textsuperscript{50,51} Numerous presenilin mutations have been identified, particularly in the presenilin 1 gene, which segregate with early onset AD and alter cleavage of APP to produce longer and more aggregating Aβ isoforms.\textsuperscript{52} The discovery that γ-secretase was involved in a ubiquitous cellular mechanism of intracellular signaling by intramembrane proteolysis, and that it cleaved myriad cellular receptors, raised major concerns regarding the potential side effects of γ-secretase inhibitors in AD treatment.\textsuperscript{53–55} Modulating γ-secretase to modify its cleavage site on APP towards production of shorter Aβ peptides – without ablating its proteolytic activity – is currently the most sought-after therapeutic approach targeting γ-secretase for AD therapy.\textsuperscript{56,57} On the other hand, active site-directed γ-secretase inhibitors have found promise in cancer treatment.\textsuperscript{58} So far, BACE1 has been considered a much safer target than γ-secretase for reducing Aβ production and preventing its accumulation in the brain, principally from comparing phenotypes of presenilin 1 knockout (which is embryonically lethal) to BACE1 gene knockout (that has no major consequences on mouse development).

**BACE1 biology**

The enzyme responsible for β-secretase cleavage of APP, and which mediates the first step in Aβ production, was simultaneously identified by five research groups in 1999–2000 (reviewed in Cole and Vassar\textsuperscript{59}). Its proposed denominations include BACE (or BACE1, to distinguish it from its homologue BACE2), memapsin 2, and aspartyl protease 2. BACE1 was demonstrated to have the expected tissue distribution and cleavage specificity of β-secretase, being highly expressed in the brain, particularly in neuronal cells, and capable of processing the APP sequence at the N-terminus of Aβ. This is in contrast to its homologue, BACE2, which does not have the correct cleavage specificity and is ubiquitously expressed, with higher expression in the peripheral tissues, such as the colon, kidney, and pancreas.\textsuperscript{60,61} BACE1 was further validated as the major β-secretase responsible for Aβ production by gene-knockout experiments, as the BACE1\textsuperscript{−/−} mice had hardly detectable levels of Aβ in their brains and BACE1\textsuperscript{−/−} cortical neuronal cultures did not produce Aβ.\textsuperscript{62–64}

BACE1 is a membrane-anchored proteolytic enzyme of the aspartyl protease family, and is synthesized as a 501-amino acid protein with a signal peptide and a prosequence\textsuperscript{65–70} (Figure 2). BACE1 is inserted in cellular membranes in the same orientation as APP.\textsuperscript{55–70} The transmembrane domain, located near the C-terminus, helps regulate BACE1 subcellular distribution and access to its substrate.\textsuperscript{27,65,71–73} The maturation and trafficking of BACE1 have been thoroughly investigated for clues towards strategies to modulate BACE1 activity and/or restrict its access to APP.\textsuperscript{73} BACE1 undergoes extensive posttranslational modifications, including removal of the prosequence and extensive glycosylation.\textsuperscript{76,73,75–77} The prosequence helps to stabilize and correctly fold the newly synthesized protein. After maturation, BACE1 is sorted in the Golgi complex and packaged for export to the endosome, which represents its main cellular site of activity because of a low pH that is optimal for this protease.\textsuperscript{73,78} Sorting of BACE1 from the Golgi complex to the endosome is mediated by Golgi-associated γ-adaptin ear adapter proteins (GGAs), which recognize an aspartyl-X-X-leucyl-leucyl motif (DXXLL) – where X represents any amino acid – at residues 496–500 in its C-terminal region.\textsuperscript{79–81} BACE1 recycles between the endosome, plasma membrane, and trans-Golgi network. Phosphorylation at serine 498 facilitates BACE1 retrieval by GGA1 from the plasma membrane to the recycling endosomes and trans-Golgi network. Palmitoylation at cysteine residues 478, 482, and 485 contributes to segregating BACE1 into lipid-raft membrane domains, away from its APP substrate.\textsuperscript{77} BACE1 cellular trafficking, compartmentalization, and turnover are tightly regulated, thereby controlling its encounter with APP,
as the two proteins follow independent trafficking routes.\textsuperscript{74} APP is endocytosed through a clathrin-dependent mechanism, whereas internalized BACE1 is sorted into vesicles containing the small guanosine triphosphatase (GTPase) adenosine diphosphate ribosylation factor 6 (ARF6), on its way to RAB GTPase 5 (RAB5)-positive early endosomes.\textsuperscript{82} Disruption of BACE1 trafficking increases its colocalization with APP and Aβ production, as exemplified when GGA expression is deficient and in AD.\textsuperscript{41,83,84} The cellular turnover of BACE1 is determined by ubiquitination at lysine 501, which tags its C-terminus for recognition by the GGA3 adaptor protein that directs its transport to lysosomal degradation, and also possibly facilitates its proteosomal degradation.\textsuperscript{85,86} Therefore, there are several stages where BACE1 maturation and trafficking could be altered to decrease its activity on APP and offer therapeutic avenues. However, the major approaches explored so far to decrease BACE1 activity on APP directly target its active site.

**BACE1 inhibitors in preclinical and clinical trials**

Publication of the crystal structure of BACE1 complexed with an inhibitor delineated its catalytic site and provided the bases for developing inhibitors.\textsuperscript{87} The active site of BACE1 contains two aspartates, which are essential for its proteolytic activity and represent the signature of the aspartyl protease class of enzymes, with these residues being included in canonical aspartyl-seryl/threonyl-glycyl motifs. The BACE1 active site is more elaborate and extended than that of other aspartyl proteases, such as renin or cathepsin D, making it challenging to design molecules capable of blocking its active site, yet small enough to penetrate cellular membranes and cross the blood–brain barrier.\textsuperscript{88–90} Most of the potent inhibitors reported so far have been selected for their inhibition of BACE1 in vitro in the cleavage reaction of a synthetic substrate based on the sequence surrounding the APP-cleavage site.\textsuperscript{91} A double mutation is introduced in the sequence, as identified in a Swedish family with early onset AD (K\textsubscript{M}670/671NL; lysyl\textsubscript{670}-methionyl\textsubscript{671} mutated to asparaginyl-leucyl) to improve cleavage efficiency.\textsuperscript{92} The enzyme source most commonly used consists of a soluble form of BACE1 that is expressed in *Escherichia coli* or in baculovirus systems, and lacks the transmembrane and cytosolic domains.\textsuperscript{87} The fact that the native cellular BACE1 associates as a homodimer and that its enzymatic activity can be enhanced by dimerization\textsuperscript{93,94} may explain some discrepancies observed for some BACE1 inhibitors between potency in vitro and cellular assays.

BACE1 inhibitors were initially designed as substrate analogs that mimicked the APP-cleavage sequence, with a nonhydrolyzable peptide bond, such as hydroxyethylene, statine analogue, and hydroxyethylamine isosteres.\textsuperscript{95,96} Sequence optimization revealed that wild-type APP was a poor substrate for BACE1, suggesting that other substrate proteins may exist.\textsuperscript{97} Inhibitor structures were fitted to maximize occupancy of the active site pockets, and were further refined to reduce their size and improve their pharmacological properties.\textsuperscript{98,99} In addition, a variety of classes of molecules capable of inhibiting BACE1 with a high potency were discovered through screening of drug libraries, particularly of aspartyl protease inhibitors prepared for drug-discovery programs targeting renin or human immunodeficiency virus protease, as well as through a fragment-based drug-discovery approach guided by X-ray and nuclear magnetic resonance structure analyses.\textsuperscript{89,99} Obtaining compounds with a selectivity of several orders of magnitude for BACE1 towards BACE2 and other aspartyl proteases, such as cathepsin D, remains a major challenge. Cathepsin D is a major lysosomal protease, and decreasing its activity would compromise the overall cellular degradation machinery.\textsuperscript{100} Whilst the function of BACE2 remains unclear, a recent publication of its substrate proteome suggests that it may play an important role in glucose metabolism in the pancreas,\textsuperscript{101} and this information should be taken into consideration when selecting a BACE1 inhibitor for clinical trials. Nonconventional inhibitors that work in an allosteric mechanism by displacing binding of the substrate have also been described.

Many published preclinical results have demonstrated the capability of proprietary compounds to block Aβ production and prevent or reverse amyloid deposition in animal models. A selection of compounds proven to be efficacious in vivo and which are undergoing or have undergone clinical trials is given in Table 1. GlaxoSmithKline was among the first companies to describe that a BACE1 inhibitor could lower Aβ levels in the brain of APP transgenic mice, using the hydroxyethylamine derivative GSK188909 (Figure 3).\textsuperscript{102} However, the application of this compound has been limited by its low brain penetration, as it is a substrate for the permeability glycoprotein, which prevents its brain delivery by active efflux.\textsuperscript{102} Ghosh et al developed the substrate analog hydroxyethylene derivative CTS-21166 (Figure 3), which can reduce Aβ levels in the brain and plasma in an AD animal model.\textsuperscript{103} Phase I clinical trials indicated that this drug was well tolerated and could decrease plasma Aβ in healthy volunteers.\textsuperscript{98} Further research led the same group to develop the hydroxyethylamine isostere GRL-8234 (Figure 3), which
<table>
<thead>
<tr>
<th>Company and compound name</th>
<th>In vitro and cellular data</th>
<th>Animal studies</th>
<th>Clinical trial stage and outcomes</th>
<th>Comments and references</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca AZD3839</td>
<td>$K_s^*=26 \text{nM/BACE1}$</td>
<td>In mice, ↓ $\text{A}\beta$ in brain and blood</td>
<td>Phase I (2013)</td>
<td>120</td>
</tr>
<tr>
<td></td>
<td>Selectivity: 14-fold/BACE1; $&gt;1,000$-fold/CatD</td>
<td>In guinea pigs, ↓ $\text{A}\beta$ in brain and CSF</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>↓ $\text{A}\beta$ and sAPPβ secretion in guinea pig cortical neurons</td>
<td>In nonhuman primates, ↓ CSF $\text{A}\beta_{1-40}$, $\text{A}\beta_{1-42}$, sAPPβ</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comentis/Astellas CTS-21166</td>
<td>$K_s^*=1.1 \text{nM/BACE1}$</td>
<td>Tg2576 mice, 8 mg/kg (intrapерitoneal injection)</td>
<td>Phase I completed (2008) in healthy volunteers</td>
<td>Low brain exposure?</td>
</tr>
<tr>
<td></td>
<td>↓ $\text{A}\beta$ secretion in CHO-APP cells (IC$_{50}^*=39$ nM)</td>
<td>50% ↓ brain $\text{A}\beta$, 70% ↓ plasma $\text{A}\beta$</td>
<td>Well tolerated (up to 225 mg) ↓ $\text{A}\beta$ in plasma</td>
<td></td>
</tr>
<tr>
<td>Eisai E2609</td>
<td>Cell-based assay, IC$_{50}^*=7$ nM</td>
<td>In rats, 10 mg/kg, -80% ↓ CSF $\text{A}\beta$ and -55% ↓ brain $\text{A}\beta$</td>
<td>Phase I completed. Well tolerated in healthy volunteers (young subjects given 5–800 mg, elderly cohort given 50 mg)</td>
<td>Headache as side effect?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In guinea pigs, 3–10 mg/kg, 85% ↓ CSF $\text{A}\beta$, 74% ↓ brain $\text{A}\beta$</td>
<td>800 mg: 92% ↓ plasma $\text{A}\beta_{1-40}$, 6 days’ lasting effect</td>
<td>Recruiting MCI patients for trials 116–119</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In nonhuman primates, ↓ plasma $\text{A}\beta_{1-40}$ and $\text{A}\beta_{1-42}$ equally (ED$_{30}=1.3\text{ nmol/L}$)</td>
<td>25 mg: 46% ↓ CSF $\text{A}\beta_{1-40}$, 200 mg: 80% ↓ CSF $\text{A}\beta_{1-42}$</td>
<td></td>
</tr>
<tr>
<td>Eli Lilly LY2811376</td>
<td>IC$_{50}^*=239$ nM/BACE1</td>
<td>In PDAPP mice, 10–100 mg/kg, 47%–68% ↓ brain $\text{A}\beta$, 56%–78% ↓ C99, 33%–63% ↓ sAPPβ</td>
<td>Phase I (2010) in healthy volunteers</td>
<td>Retinal toxicity 105</td>
</tr>
<tr>
<td></td>
<td>Lack of selectivity/Cath D</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>↓ $\text{A}\beta$ secretion in HEK-APP cells (IC$_{50}^*=300$ nM)</td>
<td>In beagle dogs, 85% ↓ plasma $\text{A}\beta$, 70% ↓ brain $\text{A}\beta$</td>
<td>↓ CSF $\text{A}\beta$ and sAPPβ</td>
<td></td>
</tr>
<tr>
<td>Eli Lilly LY2886721</td>
<td>IC$_{50}^*=20.3$ nM/BACE1</td>
<td>In PDAPP mice, ↓ brain $\text{A}\beta$, C99, sAPPβ</td>
<td>Phase I (2013) in healthy volunteers</td>
<td>Liver toxicity 106</td>
</tr>
<tr>
<td></td>
<td>Selectivity vs Cath D, pepsin and renin</td>
<td>3–30 mg/kg dose ↓ brain $\text{A}\beta$ by 20%–65%, 9-hour lasting effect</td>
<td>Ready interrupted</td>
<td></td>
</tr>
<tr>
<td></td>
<td>↓ $\text{A}\beta$ in HEK293Swe (ED$<em>{50}=1.87$ nM) and in primary neurons from PDAPP mouse (ED$</em>{50}=1.07$ nM)</td>
<td>In beagle dogs, 0.5 mg/kg dose, 50% ↓ CSF $\text{A}\beta$, 24-hour lasting effect</td>
<td>Single-dose trial (10 or 35 mg), and multiple-dose study (5, 15, or 35 mg) daily for 2 weeks</td>
<td></td>
</tr>
<tr>
<td>Merck MK-893/1</td>
<td>IC$_{50}^*=6–50$ nM/BACE1</td>
<td>In TgCRND8 (SwAPP × lnAPP) mice, 10 mg/kg, 35% ↓ brain $\text{A}\beta$ plaques, modest improvement in behavior test</td>
<td>Phase I (2010–2012) in healthy volunteers</td>
<td>Phase III in progress 112–115</td>
</tr>
<tr>
<td></td>
<td>100% selective vs Cath D</td>
<td></td>
<td>Well tolerated (2.5–550 mg) 20-hour half-life</td>
<td></td>
</tr>
<tr>
<td></td>
<td>↓ $\text{A}\beta$ secretion in cells (IC$_{50}^*&lt;1.00$ nM)</td>
<td>In monkeys, 20–60 mg/kg, 14 days</td>
<td>Single dose (100 or 500 mg), &gt;90% ↓ CSF $\text{A}\beta_{1-40}$ and Aβ$<em>{1-42}$; multiple dose (10 mg), 50% ↓ CSF $\text{A}\beta</em>{1-40}$; 40 mg, 80% CSF ↓ $\text{A}\beta_{1-42}$; In patients with mild to moderate, daily dose (12–80 mg) for 7 days ↓ CSF $\text{A}\beta_{1-40}$, Aβ$_{1-42}$, and sAPPβ</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** BACE1, β-site amyloid precursor protein–cleaving enzyme; Cath D, cathepsin D; $\text{A}\beta$, amyloid-β; sAPP, soluble N-terminal fragment of amyloid precursor protein; IC$_{50}$, 50% inhibitory concentration; ED$_{50}$, 50% effective dose; CSF, cerebrospinal fluid; Tg, transgenic.
showed high potency against BACE1 in vitro and in cells, and also a good selectivity for BACE1 compared to BACE2 and cathepsin D. Furthermore, they demonstrated that this drug could penetrate the brain and sustain a reduction of plasma and brain Aβ for 12 hours in Tg2576 AD mice. Chronic administration over 6 months was well tolerated in the mice, and led to a large decrease of plasma Aβ and Aβ. Behavioral tests following chronic administration showed improved cognitive performance that paralleled a decrease in brain amyloid burden. This study demonstrates that BACE1 inhibition can reduce amyloid deposition in the brain and rescue memory deficits in an animal model, and thus supports the feasibility of BACE1 inhibition for AD therapy. The major limitation of this drug is that it could not be administrated orally and was given by intravenous injection, or for prolonged treatment, through implanted osmotic pumps.

Lilly Research Laboratories have developed several classes of potent BACE1 inhibitors. Preclinical trials of LY-2811376 (Figure 3), a nonpeptidic inhibitor designed from a fragment-based screening approach, were very promising, and showed that this drug had good bioavailability and high efficacy in vivo. A dose-dependent reduction of Aβ levels was demonstrated in the brain of an AD mouse model. The encouraging results of trials in beagle dogs prompted testing of this compound in humans. In Phase I clinical trials, the drug proved to be very efficacious at reducing Aβ and sAPPβ levels in the CSF of healthy volunteers, and seemed to be well tolerated. However, clinical trials were discontinued as a safety measure after parallel toxicity studies in rats pointed to retinal toxicity, which was attributed to a lack of specificity of the compound and its interference with cathepsin D. Soon afterwards, Lilly began Phase I trials of LY-2886721 (Figure 3), a compound with proven good selectivity for BACE1 against renin and cathepsin D and promising results in preclinical studies. In spite of a relatively short half-life of 3 hours, a dose-dependent inhibition of Aβ, C99, and sAPPβ was observed in the brain of AD mice that received the drug orally. Further preclinical trials in beagle dogs showed that a dose of 0.5 mg/kg could achieve a 9-hour-lasting 50% decrease in CSF Aβ and a 24-hour decrease in plasma Aβ. Phase I trials were then conducted, in which healthy volunteers received either a single dose or repeated doses of the drug over a period of 2 weeks. CSF analysis

Figure 3 Published chemical structure of β-site amyloid precursor protein-cleaving enzyme 1 inhibitors in preclinical and clinical trials. The precise structure of Pfizer compound PF-05297909 has not been disclosed, but it is presumably derived from the general formula given in Brodney’s United States Patent and Trademark Office application 2011022431, where R1 and R1’ are each independently hydrogen, alkyl, or alkenyl, R2 is alkyl, cycloalkyl, or alkenyl, B is alkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, and A is independently aryl, cycloalkyl, heterocycloalkyl, or heteroaryl.
showed decreases of up to 74% in Aβ1-40, 71% in Aβ1-42, and 77% in sAPPβ concentrations, with a simultaneous increase in sAPPα (−50%). These data show the proof of principle that BACE1 inhibition can achieve its expected outcomes in humans. However, reports of liver toxicity in some of the participants led to interruption of the human trials.

Merck researchers have developed several lead compounds that were identified through screening of a million compounds from drug libraries, and these have produced a large number of molecules that potently inhibit BACE1 in vitro. Trials of selected drugs in primate models have shown very promising potential, with near-complete inhibition of Aβ levels in the brain and CSF. Compound MK-8931 has now progressed to Phase II clinical trials, and presentations at conferences suggest this is currently the most advanced BACE1 inhibitor in human trials. Phase I was carried out in two separate centers on small cohorts of 18- to 45-year-old subjects, with healthy volunteers in Belgium receiving a single dose of the compound (2.5–550 mg), and another group of healthy volunteers in the US receiving multiple rising doses (20, 100, 550 mg), and mild-to-moderate adverse effects being reported. Subjects who received a single dose had their CSF Aβ levels decrease by up to 79%, with a sustained 36-hour effect. Phase II studies are now being conducted, with no serious adverse effects reported to date.

A recent trial in mild-to-moderate AD patients who were given 12–60 mg of MK-8931 for 7 days showed a dose-dependent and sustained reduction in CSF levels of Aβ40 (up to 84%), Aβ42 (up to 81%), and sAPPβ (up to 88%).

Scientists at Eisai have reported detailed preclinical results of the small-molecule BACE1 inhibitor E2609. The compound showed a dose-dependent decrease of up to ~80% in CSF and up to ~75% in brain Aβ levels after a single-dose administration to rats and guinea pigs. An impressive and sustained reduction of CSF Aβ1-40 and Aβ1-42 levels was also observed in nonhuman primates after oral administration to cynomolgus monkeys. A Phase I trial of E2609 has also been completed successfully, with the compound being well tolerated. Single-dose administration of 5–800 mg of compound to healthy volunteers aged 30–55 years, and of 50 mg given to an elderly cohort aged 65–85 years, showed a dose-dependent prolonged reduction in plasma Aβ levels. Multiple ascending doses given for 2 weeks produced a sustained decrease of Aβ40 and Aβ42 levels in the CSF. This compound is now being trialed in Phase II in subjects with mild cognitive impairment.

AstraZeneca also has a development program on BACE1 inhibitors at an advanced stage, and has recently released preclinical data of drug candidates. Crystal structure-aided refinement of a lead compound that was identified through fragment-based screening achieved the design of AZD3839 (Figure 3), which is orally available and has a good selectivity for BACE1 compared to BACE2 (14-fold) and cathepsin D (>1,000-fold). Preclinical data showed low nanomolar in vitro potency of AZD3839 (K = 26 nM) and its efficacy in cellular assays, including inhibition of Aβ and sAPPβ secretion from guinea pig primary cortical neurons. Studies in animal models indicated a sustained reduction in the levels of Aβ in the brain and plasma of wild-type mice and guinea pigs. CSF analysis in guinea pigs administered the drug showed a decline in Aβ40 that paralleled the decline of Aβ levels in the brain. Intravenous perfusion in cynomolgus monkeys reduced the levels of Aβ40, Aβ42, and sAPPβ in the CSF. Thus, AZD3839 appears to be a valid and promising drug candidate for lowering Aβ levels in the brain, and it is currently in Phase I human trials. Another compound, AZ-4217 (Figure 3), also proved to be highly potent in vitro and efficient at lowering Aβ levels and deposition in the brain of an AD mouse model, but it lacks selectivity for BACE1 compared to BACE2. Another AstraZeneca compound, AZD3293, was also recently reported to have the preclinical profile of a drug candidate.

Pfizer researchers have also conducted Phase I safety evaluation of the spirocyclic lactam BACE1 inhibitor PF-05297909 (Figure 3). This compound was well tolerated at doses ranging from 25 to 325 mg, and was able to decrease Aβ levels in plasma; however, it did not induce any changes in CSF Aβ levels, suggesting that insufficient amounts were delivered to the brain.

All the compounds described thus far are competitive inhibitors that directly target the BACE1-active site, and therefore block its enzymatic activity. In contrast, Takeda researchers have developed a noncompetitive inhibitor, TAK-070, which is a small lipophilic molecule that was uncovered through screening of drug libraries. TAK-070 is specific for BACE1, and disrupts the interaction of BACE1 with APP through fragment-based screening achieved the design of AZD3839 (Figure 3), which is orally available and has a good selectivity for BACE1 compared to BACE2 (14-fold) and cathepsin D (>1,000-fold). Preclinical data showed low nanomolar in vitro potency of AZD3839 (K = 26 nM) and its efficacy in cellular assays, including inhibition of Aβ and sAPPβ secretion from guinea pig primary cortical neurons. Studies in animal models indicated a sustained reduction in the levels of Aβ in the brain and plasma of wild-type mice and guinea pigs. CSF analysis in guinea pigs administered the drug showed a decline in Aβ40 that paralleled the decline of Aβ levels in the brain. Intravenous perfusion in cynomolgus monkeys reduced the levels of Aβ40, Aβ42, and sAPPβ in the CSF. Thus, AZD3839 appears to be a valid and promising drug candidate for lowering Aβ levels in the brain, and it is currently in Phase I human trials. Another compound, AZ-4217 (Figure 3), also proved to be highly potent in vitro and efficient at lowering Aβ levels and deposition in the brain of an AD mouse model, but it lacks selectivity for BACE1 compared to BACE2. Another AstraZeneca compound, AZD3293, was also recently reported to have the preclinical profile of a drug candidate.

Pfizer researchers have also conducted Phase I safety evaluation of the spirocyclic lactam BACE1 inhibitor PF-05297909 (Figure 3). This compound was well tolerated at doses ranging from 25 to 325 mg, and was able to decrease Aβ levels in plasma; however, it did not induce any changes in CSF Aβ levels, suggesting that insufficient amounts were delivered to the brain.

All the compounds described thus far are competitive inhibitors that directly target the BACE1-active site, and therefore block its enzymatic activity. In contrast, Takeda researchers have developed a noncompetitive inhibitor, TAK-070, which is a small lipophilic molecule that was uncovered through screening of drug libraries. TAK-070 is specific for BACE1, and disrupts the interaction of BACE1 with APP through fragment-based screening achieved the design of AZD3839 (Figure 3), which is orally available and has a good selectivity for BACE1 compared to BACE2 (14-fold) and cathepsin D (>1,000-fold). Preclinical data showed low nanomolar in vitro potency of AZD3839 (K = 26 nM) and its efficacy in cellular assays, including inhibition of Aβ and sAPPβ secretion from guinea pig primary cortical neurons. Studies in animal models indicated a sustained reduction in the levels of Aβ in the brain and plasma of wild-type mice and guinea pigs. CSF analysis in guinea pigs administered the drug showed a decline in Aβ40 that paralleled the decline of Aβ levels in the brain. Intravenous perfusion in cynomolgus monkeys reduced the levels of Aβ40, Aβ42, and sAPPβ in the CSF. Thus, AZD3839 appears to be a valid and promising drug candidate for lowering Aβ levels in the brain, and it is currently in Phase I human trials. Another compound, AZ-4217 (Figure 3), also proved to be highly potent in vitro and efficient at lowering Aβ levels and deposition in the brain of an AD mouse model, but it lacks selectivity for BACE1 compared to BACE2. Another AstraZeneca compound, AZD3293, was also recently reported to have the preclinical profile of a drug candidate.

Pfizer researchers have also conducted Phase I safety evaluation of the spirocyclic lactam BACE1 inhibitor PF-05297909 (Figure 3). This compound was well tolerated at doses ranging from 25 to 325 mg, and was able to decrease Aβ levels in plasma; however, it did not induce any changes in CSF Aβ levels, suggesting that insufficient amounts were delivered to the brain.
Ferretti et al at McGill University have uncovered a novel approach to BACE1 inhibition by studying the effect of minocycline in an AD mouse model with abnormally high levels of BACE1. Minocycline, which is an anti-inflammatory and neuroprotective drug, was given to the mice at an early age, prior to amyloid deposition. Treatment between the ages of 1 and 3 months significantly decreased brain Aβ levels. Further analysis showed that minocycline not only decreased inflammation markers but also restored BACE1 expression and enzymatic activity to normal levels, through modulation of the nuclear factor κB pathway. These data are promising, although the toxicity of the drug was noticed.

Other approaches for interfering with BACE1 activity and cleavage of APP have been explored. These include silencing BACE1 gene expression by small interfering ribonucleic acid (siRNA), and immunotherapeutic strategies targeting BACE1 directly, or targeting the BACE1 cleavage site of APP.

### How safe is BACE1 inhibition? Lessons from gene-knockout models

Suppression of BACE1 expression in animal models has shed light on the potential consequences of the complete pharmacological inhibition of BACE1 and revealed that BACE1 cleaved substrates other than APP. The list of these substrates is given in Table 2, and the identified cleavage sites summarized in Table 3.

The first reports of BACE1 gene knockout in mice indicated no overt phenotype, and supported the safety of BACE1 inhibition in AD therapy. The mice were shown to develop normally, and by the age of 12 months showed no gross morphological defect or abnormality in tissue weights, hematology, or clinical chemistry. Importantly, BACE1 gene knockout abolished Aβ production in the brain and increased processing of APP by the α-secretase pathway. Neuronal cultures derived from the BACE1−/− mice did not produce any detectable amount of Aβ42, thus establishing BACE1 as the major β-secretase activity in neurons, and supporting the view that inhibiting its activity would abolish Aβ production. Crossbing the BACE1−/− mice with transgenic mouse models of AD, or partial genetic deletion of BACE1 in the AD mice, decreased brain amyloid load and rescued memory deficits and synaptic activity, thereby supporting the potential benefits of BACE1 inhibition in AD.

However, closer monitoring of the BACE1-null mice indicated an increased perinatal mortality, and the survivors were hyperactive and smaller than their wild-type counterparts. Thorough examination uncovered histological abnormalities as well as behavioral phenotypes, beginning to reveal that BACE1 cleaved substrates other than APP. BACE1−/− mice displayed hypomyelination in the peripheral nervous system and altered axonal sorting of unmyelinated neurons into Schwann cell bundles, akin to what is observed in the NRG1−/− knockout (NRG1−/−) mice or in mice that lack Schwann cells’ epidermal growth-factor receptor (ErbB) signaling. Willem et al further demonstrated that BACE1 was required for proper myelin-sheath formation through the processing of type III Nrg1, as full-length uncleaved type III Nrg1 accumulated in the BACE1−/− mice. Although BACE1 knockout did not prevent maturation of oligodendrocytes or construction of the myelin sheath, it reduced the expression of myelin proteins, such as myelin basic protein. Considering that the expression of BACE1 and type III Nrg1 is highest in the early postnatal stage, which is a critical period for neuron myelination, it has been proposed that BACE1 inhibitors would not affect neuron myelination in mature adults and elderly patients. However, recent research indicates that Nrg1 promotes remyelination in adults, and that the remyelination process after injury is decreased in the BACE1−/− knockout mice, with accumulation of unprocessed type III Nrg1 and its homologue Nrg3, which was thereby revealed to be another BACE1 substrate, and to also take part in the remyelination process. The BACE1 cleavage site of type III Nrg1 was identified at position 237–238, between a phenylalanine (F) and a methionine (M), on the C-terminal side near the juxtamembrane region (Table 3). The BACE1 cleavage site is located within a sequence that is only present in Nrg1 variants, type I, and type III, and in Nrg3, and it is totally conserved among vertebrates.

The BACE1-null mice also showed defects in myelination in the central nervous system – principally in the hippocampus and cerebral cortex – and schizophrenia-like behavior phenotypes. These include novelty-induced hyperactivity and impaired social interactions, as well as a decrease in prepulse inhibition and cognitive deficits in the Morris water maze. These phenotypes can be attributed to disruptions of the Nrg1/ErbB4 signaling cascade, which has been associated with schizophrenia. Experimental studies have demonstrated that the Nrg1/ErbB4 system regulates synaptic activity and plasticity, and thus its perturbation causes cortical deficits that can result in glutamatergic hypofunction. Therefore, it was essential to investigate the consequences of BACE1 knockout on Nrg1 downstream signaling that involves the activation of ErbB4 receptors, which in turn activates a signaling kinase cascade that modulates synaptic...
<table>
<thead>
<tr>
<th>Substrate protein</th>
<th>Biological function</th>
<th>Role of BACE1 cleavage</th>
<th>Consequence of BACE1 knockout, or inhibition</th>
<th>Consequence of BACE1 increased expression</th>
</tr>
</thead>
</table>
| Amyloid precursor protein (APP) | - Regulation of neurite outgrowth, synapse formation, and synaptic plasticity<sup>21</sup>  
- Metal homeostasis<sup>22</sup> | - Aβ production<sup>66</sup>  
- sAPPβ ectodomain shedding, leading to activation of DR6, to regulate axon pruning<sup>28</sup>  
- Regulation of cortical plasticity in adult? | - Suppression of Aβ production<sup>62-64,142</sup>  
- Reduced plaque formation and rescue of cognitive deficits in AD models<sup>138,141</sup> | - Aβ amyloid accumulation and neuronal death<sup>35,37,83</sup> |
| Amyloid precursor-like proteins (APLP1 and APLP2) | - Regulation of neurite outgrowth, synapse formation, and synaptic plasticity<sup>21</sup>  
- Glucose metabolism and insulin homeostasis<sup>210</sup> | - Ectodomain shedding | - Unknown | - Unknown |
| Neuregulin 1 (Nrg1) type IIIβ | - Regulation of myelination, oligodendrocyte differentiation, neuronal migration  
- Regulation of neurotransmitter receptors and synaptic plasticity<sup>144,213,214</sup> | - Nrg1 type III precursor cleavage to induce activation of ErbB receptors<sup>144,152,211</sup>  
- Nrg1 type IIIβ1 cleavage to regulate formation and maintenance of muscle spindles<sup>159</sup> | - Hypomyelination of peripheral and central nervous systems<sup>144,146</sup>  
- Schizophrenia-like phenotypes improved by antipsychotics<sup>146</sup>  
- Synaptic deficits<sup>212</sup>  
- Deficits in motor coordination<sup>179</sup>  
- Seizures (unrelated to aberrant sodium-channel activity)<sup>142,165</sup> | - Defective remyelination<sup>149</sup>  
- Seizures<sup>142,165</sup>  
- Epileptic activity | - Unknown |
| Neuregulin 3 (Nrg3) | - Remyelination<sup>149</sup>  
- Regulation of sodium-channel activity (neuronal membrane – excitability and propagation of action potentials)<sup>162</sup> | - Cleavage activation<sup>149</sup>  
- Cleavage of VGSC β-subunits to repress cell-surface expression of Na channels and regulate sodium currents<sup>164-166</sup> | - Seizures<sup>142,165</sup> | - Unknown |
| Voltage-gated sodium channel (VGSC) auxiliary β-subunits β1-4 | - Regulation of muscle-spindle formation and maintenance<sup>214</sup> | - Nrg1 type IIIβ1 cleavage to regulate formation and maintenance of muscle spindles<sup>159</sup> | - Defective remyelination<sup>149</sup>  
- Seizures<sup>142,165</sup>  
- Epileptic activity | - Unknown |
| Potassium voltage-gated channel ancillary subunits KCNE1 and KCNE2 | - Modulation of potassium-channel trafficking and activity (membrane excitability in brain and heart)<sup>215</sup> | - Cleavage of KCNE to control potassium-channel activity and cell-surface expression<sup>171</sup>  
- Downregulates transferase activity<sup>78</sup> | - Seizures (unrelated to aberrant sodium-channel activity)<sup>170</sup> | - Seizures (unrelated to aberrant sodium-channel activity)<sup>170</sup> | - Unknown |
| Beta-galactoside alpha2,6-sialyltransferase (ST6Gal I) | - Negative regulator of galectin (involved in adhesion, migration, proliferation, and apoptosis)<sup>216</sup> | - Downregulates transferase activity<sup>78</sup> | - Altered control of immune response?  
- Loss of control of cell adhesion and proliferation  
- Altered control of inflammatory response?  
- Autoimmune disease?  
- Temper immune and inflammation mechanisms? | - Reduced cancer proliferation? | - Reduced cancer proliferation? |
| P-selectin glycoprotein ligand-1 (PSGL1 or SELPLG) | - Cell adhesion<sup>217</sup>  
- Response to injury (recruitment of white blood cells to inflamed tissue)<sup>217</sup> | - Cleavage of SELPLG<sup>185</sup>  
- Limits cell adhesion?  
- Altered control of inflammatory response?  
- Autoimmune disease?  
- Temper immune and inflammation mechanisms? | - Altered control of cell adhesion and proliferation  
- Loss of control of inflammatory response?  
- Modulate immune and inflammation mechanisms? | - Reduced cancer proliferation? | - Reduced cancer proliferation? |
| Interleukin 1 receptor 2 (IL-1R2) | - Decoy receptor for IL1  
- Regulates immune and inflammatory responses | - IL-1R2 secretion<sup>186</sup>  
- Limit inflammatory response? | - Loss of control of inflammatory response  
- Modulate immune and inflammation mechanisms? | - Reduced cancer proliferation? | - Reduced cancer proliferation? |
| Low-density lipoprotein receptor-related protein (LRP) | - Endocytosis and lipid homeostasis (ApoE receptor)<sup>218</sup>  
- Clearance mechanisms<sup>218</sup> | - Ectodomain shedding, LRPI secretion<sup>182</sup> | - Decreased lipid metabolism and Aβ clearance?  
- Alteration of lipid metabolism and Aβ clearance? | - Decreased lipid metabolism and Aβ clearance?  
- Alteration of lipid metabolism and Aβ clearance? | - Decreased lipid metabolism and Aβ clearance?  
- Alteration of lipid metabolism and Aβ clearance? |

(Continued)
plasticity, long-term potentiation, and Src kinase activation of N-methyl-D-aspartate (NMDA) receptors. Biochemical analysis of the brain of the BACE1-null mouse revealed decreased phosphorylation of the Akt/phosphatidylinositol 3-kinase, which attenuates an interaction between ErbB4 and the postsynaptic density protein PSD95, and thus alters the postsynaptic membrane composition and the function of NMDA receptors. BACE1 knockout also decreased the expression of DISC1, a gene associated with psychiatric disorders and involved in brain development and neuronal migration, and which has recently been shown to regulate NMDA receptors. A report of aberrant spine morphology and significantly reduced number of spine dendrites in the hippocampal CA3–CA1 pathway of BACE1−/− mice is consistent with the important role of Nrg1/ErbB4 signaling in the maintenance of synaptic function and plasticity. Severe deficits in mossy fiber synapses with an absence of long-term potentiation is another feature of BACE1−/− mice, which may be attributed to defective processing of both Nrg1 and the β-subunits of voltage-gated sodium channels (VGSCs), as developed below.

A recent study has also reported deficits in muscle coordination in BACE1−/− mice, which are due to improper processing of Ig-Nrg1 type I β1, an Nrg1 isoform that plays an important role in the development, maturation, and maintenance of muscle spindles. Pharmacological or genetic ablation of BACE1 activity in adult mice demonstrated that BACE1 was required to sustain the muscle sensory system and regulate movement coordination.

Other behavior phenotypes of the BACE1-null mice included hyperactivity and an increased susceptibility to seizures, which suggested improper sodium-channel activity. Electrophysiological experiments revealed subtle alterations in the inactivation of VGSC in BACE1-deficient neurons. Furthermore, when the AD mouse model PDAPP was crossed with BACE1−/−, it performed unexpectedly worse than the
original PDAPP and the PDAPP/BACE1−/− heterozygous, being slower at swimming, showing increased memory deficits, and being more frequently subject to seizures.160 Four-year monitoring of a BACE1−/− mouse colony showed that approximately 30% of these animals died soon after birth as a consequence of seizures. Among the survivors, 11% had seizures before the age of 1 month, and this frequency rose to 14.7% in mice aged 3–6 months and reached 21.9% in mice older than 10 months.161 Electrophysiological activity was altered in the brain of the overall BACE1−/− mouse population, as demonstrated by abnormal wave–spike discharges recorded by electroencephalography and an increased susceptibility to kainate-induced epileptic activity.161 These abnormalities reflect impaired sodium-channel activity. VGSCs are comprised of a heteromeric complex of one large α-subunit (Na,1) and one or two β-subunits (VGSCβ). The β-subunits, which show some homology to cell-adhesion molecules, are known to modulate gating of the channel and to regulate the surface expression of the α-subunit, thus leading to the formation of the ion-conducting pore.162,163 Several independent studies have identified each of the four VGSCβs as substrates for BACE1 cleavage.143,164–168 RNA-interference experiments in mouse embryonic fibroblasts overexpressing any of the four VGSCβ homologues have established their proteolytic processing by BACE1 and γ-secretase.168 Furthermore, biochemical analysis of the brain of BACE1-null mice showed altered processing of VGSCβ.168,169 Pharmacological manipulation of BACE1 activity as well as BACE1 gene knockout decreased the levels of Na,1.1 messenger RNA and protein in rat cortical and hippocampal neurons, supporting the view that BACE1 cleavage of the β subunits and subsequent release of their transcriptionally active intracellular domains controls the expression of the α-subunits and formation of the channel at the cell surface.169 A decrease of Na,1.1 in BACE1-null mice was observed at 1 and 3 months, indicating that endogenous BACE1 activity regulates the levels of Na,1.1 in developing and adult neurons. Furthermore, at 1 month, the BACE1-knockout mice showed increased expression of Na,1.2 and its accumulation at the neuronal surface, which would cause an imbalance in sodium-channel activity and may explain the seizure phenotypes observed in these animals.168 However, another study which corroborated seizure activity and hypersensitivity in the BACE1−/− mice, but to demonstrate a correlation between the expression and surface localization of Na,1.2 and seizure activity.170 It was also demonstrated that BACE1 regulates the excitability of cerebellar neurons by processing the Na+ channel β4-subunit.167 The recent identification of the auxiliary subunits of the potassium voltage-gated channels KCNE1 and KCNE2 and that of the seizure 6 protein as additional BACE1 substrates adds to the complexity of BACE1 physiological function in the brain.101,171

**Functional diversity of BACE1 substrates**

Besides the major substrates identified in the BACE1 knockout mice, additional substrates were also revealed by other approaches (a comprehensive list of identified BACE1 substrates and their function is given in Table 2 and the identified cleavage sites of BACE1 substrates are given in Table 3). The APP homologues, ALP1 and ALP2 were first investigated and experimentally demonstrated to undergo BACE1-dependent proteolysis by pharmacological and genetic manipulation of BACE1 activity,101,172–174 and their cleavage products were characterized.173,175 They were also harvested as BACE1 substrates in systematic proteomics studies.101,176 The function of the APP homologues remains unknown, but their expression in the central nervous system has been linked to synaptic plasticity and memory consolidation.21 Their role in glucose metabolism and insulin homeostasis has also been documented. And the function of APP itself remains to be taken into consideration. Although it is usually assumed that inhibiting BACE1 cleavage of APP would be beneficial by reducing Aβ production and preventing cell death, the apparently regulated and sophisticated processing of APP merits further investigation. It is important to consider that the cleavage of APP by BACE1 also releases sAPPβ, which is the precursor to a ligand for the death receptor 6 (DR6) that, not only regulates axon pruning during brain development,28 but has now been shown to contribute to regulating cortical plasticity in adults.177 The DR6 knockout mice show deficits in sensory experience caused by defects in axonal pruning that affect long-range horizontal excitatory connections and inhibitory neurons. Thus, the consequences of altering BACE1 activation of DR6 receptors will need further scrutiny.

BACE1 was also shown to process several proteins that contribute to cellular metabolism and trafficking. Among these is the Golgi-resident enzyme, β-galactoside alpha2,6-sialyltransferase (ST6Gal I),178,179 which modifies selected glycoproteins and acts as a negative regulator of galectin binding and function.180 This enzyme is abundantly expressed in the liver from where it becomes secreted into the plasma, particularly during hepatic acute inflammation. A marked decrease in ST6Gal I secretion was observed in the plasma of the BACE1 knockout mice. Furthermore, alterations
of BACE1 expression in rodent models induced changes in plasma levels of ST6Gal I that paralleled changes in BACE1 levels.\textsuperscript{131} The multifunctional endocytic and signaling receptor, low-density lipoprotein receptor related protein (LRP) also undergoes processing by BACE1, which results in the secretion of its extracellular domain.\textsuperscript{132} Its homologue, LRP4 was also picked up by proteomics analysis.\textsuperscript{176} LRP1 was recently shown to be involved in neuronal mechanisms that clear apoptotic cells and myelin debris,\textsuperscript{183} and to mediate Schwann cell-axon interactions, particularly following peripheral nervous system (PNS) injury.\textsuperscript{184} Other identified BACE1 substrates participate in cell adhesion and in the inflammatory response. These include the P-selectin glycoprotein ligand 1 (PSGL-1), which promotes leukocyte adhesion in the inflammatory response,\textsuperscript{185} and the decay receptor, interleukin-1 receptor 2 (IL1-R2), which modulates interleukin 1 in the brain.\textsuperscript{186} The neural cell adhesion molecules, L1, close homologue of L1 (CHL1) and contactin-1 were identified as BACE1 substrates through proteomics screens and further validated in vivo.\textsuperscript{186,\textsuperscript{187}} The examination of BACE1 \textit{null} mouse brain revealed axon guidance defects in the hippocampus and olfactory bulb,\textsuperscript{188-190} which closely resemble the CHL1\textsuperscript{−/−} phenotype.\textsuperscript{188}

Following report of the retinal toxicity of the Lilly BACE1 inhibitor LY-2811376, researchers have examined the retina of BACE1\textsuperscript{−/−} mice for signs of pathology and discovered some abnormalities.\textsuperscript{191} The retina of the BACE1\textsuperscript{−/−} mice is thinner compared to wild type mice, and displays defects in vascularization. These defects are associated with impaired shedding and signaling of the vascular endothelial growth factor receptor 1 (VEGFR1) and can be replicated by treatment with a BACE1 inhibitor of a different chemical class to LY-2811376. An accumulation of lipofuscin age pigment is also observed in retinal pigment epithelial cells that have been treated with BACE1 siRNA or with a BACE1 inhibitor, which reflects the perturbation of lysosomal function. These data suggest that the retinal toxicity of LY-2811376 was the direct consequence of BACE1 inhibition and highlight the importance of elucidating BACE1 biology and closely monitoring the side-effects of BACE1 inhibitors in clinical trials.

Proteomics screens of neuronal and non-neuronal cells, with either deficiency or overexpression of BACE1, have helped to define the BACE1 “sheddome” – the set of receptor proteins that are shed by BACE1 – and discover potential for a series of new substrates that, according to their function, can be subdivided into trafficking proteins (ie, sortilin 1 and sortilin receptor SorL1, semaphorins), proteases (ie, endothelin-converting enzyme 1, aminopeptidase A, carboxypeptidase D), cell adhesion molecules (ie, glypican-3, NCAM1, L1, contactin-1), receptors and co-receptors (mannose-6-phosphate receptor, syndecan-4), and importantly, proteins involved in cell–cell contact and intercellular communication (contactin-1, Jagged-1, ephrin receptors, protocadherins, reelin).\textsuperscript{100,\textsuperscript{176,\textsuperscript{192}} These substrates consist mainly of type I integral proteins, and also of a few type II and glycosylphosphatidylinositol (GPI)-anchored proteins. Parallel characterization of the BACE2 “sheddome” in pancreatic cells has revealed non-redundant roles for the two protease homologues, although some mutual compensatory mechanisms were also observed.\textsuperscript{101} Therefore the selectivity of BACE1 inhibitors remains an important issue as cross-reactivity with BACE2 may lead to unwanted side-effects.

Overall, the findings from the \textit{BACE1} knockout mice warn of the potential dangers of eliminating BACE1 activity in humans. The risks of BACE1 ablation may even accrue when some other substrates that were recently uncovered by proteomics studies become further validated.

**Detriments of BACE1 elevation and potential benefits of BACE1 inhibition**

Studies of post-mortem brain tissue have pointed to a significant (up to two- or three-fold) increase in BACE1 protein levels in AD patients.\textsuperscript{35-41} The most obvious consequence of elevated BACE1 – which has been confirmed by experimental analysis – is the overproduction of Aβ peptides\textsuperscript{193} and amyloidogenic fragments.\textsuperscript{35} This has been replicated in several mouse models.\textsuperscript{194-196} However, insufficient effort has so far been dedicated towards investigating additional consequences of BACE1 overexpression. Indeed, considering the role of BACE1 substrates in fine-tuned signaling systems in the brain, it is equally important to examine adverse effects of a BACE1 gain-of-function, as those of a BACE1 loss-of-function, in order to fully evaluate the benefits of a BACE1-targeting therapy. BACE1 overexpression in transgenic mice causes excessive Na\textsubscript{+}β\textsubscript{2} cleavage, which results in decreased surface expression of VGSC1, with consequent reduced propagation of action potentials and impaired neuronal activity.\textsuperscript{162} Excessive processing of Na\textsubscript{+}β\textsubscript{2} due to elevated BACE1 may underlie the increased incidence of epileptic seizures, which has been observed in AD patients.\textsuperscript{199,\textsuperscript{200}} Examination of an APP transgenic mouse model of AD has revealed high BACE1 expression, increased processing of Na\textsubscript{+}β\textsubscript{2}, and accumulation of Na\textsubscript{+}β\textsubscript{2} fragments in the nucleus of GABAergic and non-GABAergic neurons, which were associated with defects in neuronal activity and impaired performance in cognitive behavior tests.\textsuperscript{201}
In addition, the CD1 mouse, a pharmacological model of temporal epilepsy, showed increased BACE1 immunoreactivity and Na_2 processing in the limbic system, and abnormal axonal sprouting. These data highlight potential harmful effects of increased BACE1 activity linked to aberrant sodium channel activity. Whether increased BACE1 activity and increased sAPPβ production may lead to over-activation of DR6 receptors and alter synaptic plasticity also remain to be investigated.

Can BACE1 inhibitors offer additional benefits to Aβ reduction? As described above, many studies have shown the benefits of BACE1 inhibitor treatment to reduce Aβ levels and prevent neuronal loss in animal models. Interestingly, the close observation of BACE1−/− mice showed a reduction in body weight, with increased energy expenditure and reduced metabolic efficiency, as well as increased glucose disposal and insulin sensitivity. These mice are also protected against high fat diet-induced obesity. Pharmacological reduction of BACE1 activity by Merck-3 inhibitor in a skeletal muscle cell line also increased insulin signaling and glucose uptake. These results suggest a role for BACE1 in glucose homoeostasis, which is further supported by proteomics studies. As type 2 diabetes is being proposed as a possible risk factor for AD, determining if BACE1 inhibition may help fight insulin resistance and decrease blood glucose levels would require future interest. Another positive effect of BACE1 reduction is the enhanced clearance of myelin debris and accelerated regeneration of peripheral axons and the reinnervation of neuromuscular junctions after injury, as evidenced in BACE1−/− mice. Treatment with a BACE1 inhibitor also improved axonal injury recovery in wild type mice.

**Conclusion**

Cleavage of APP by BACE1 triggers Aβ production and initiates the amyloid cascade of AD. For this reason, BACE1 represents a rational and attractive therapeutic target. Extensive preclinical trials have proved the efficacy of BACE1 inhibitors at lowering Aβ levels in the brain and at rescuing cognitive deficits in AD animal models. However, BACE1 gene knock-out experiments have offered some insight into the physiological function of BACE1 and warned of the risks associated with total eradication of its activity. BACE1 appears to play an important role in the developing central and peripheral nervous system, and to be also required for the maintenance and repair of these systems, particularly in response to injury and inflammation. Thus, we propose that safe therapies based on BACE1 inhibition should principally be addressed to patients with demonstrated high BACE1 activity, and be aimed to restore BACE1 to normal levels, but not suppress it. Recent findings from human genetic studies suggest that the position of the balance between the amyloidogenic and non-amyloidogenic processing of APP has direct implications to AD pathogenesis (refer to Figure 1). The Icelandic APP mutation, which shifts this balance towards the non-amyloidogenic pathway by lessening β-secretase cleavage was found to protect its carriers against age-related cognitive decline and dementia. Conversely, the newly identified missense mutations in the ADAM10, α-secretase gene increase the risk of developing late-onset AD by attenuating α-secretase activity, thus favoring APP processing through the β-secretase/BACE1 pathway. These results further validate the amyloid hypothesis and support a pharmacological intervention targeting BACE1 to restore the balance between α and β cleavages of APP. An early intervention will be recommended, as PET imaging studies have demonstrated that Aβ starts accumulating in the brain before the first signs of cognitive impairment are observed, and 20–30 years before a clinical AD diagnosis is established and irreparable neuronal loss has occurred. Thus, it will be essential to monitor early changes in biomarkers that indicate an increase in BACE1 levels, and to define the range of normal BACE1 activity in the brain or CSF. For this purpose, some of the newly identified BACE1 substrates may provide novel biomarkers to aid quantify BACE1 activity and control the effects, positive and negative, of BACE1 inhibitor therapy. Further development of strategies to modulate the interaction of BACE1 with APP should also be pursued.

**Acknowledgments**

The authors acknowledge the help of Duncan E Campbell with editing the revised version of the manuscript, and the funding support from the NHMRC (Dora Lusch postgraduate scholarship to AB).

**Disclosure**

The authors have no conflicts of interest in this work.

**References**


